Subodh Verma
YOU?
Author Swipe
View article: Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management
Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management Open
View article: Frailty and Effects of Semaglutide in Obesity-Related HFpEF
Frailty and Effects of Semaglutide in Obesity-Related HFpEF Open
Semaglutide resulted in a similar reduction in BW across frailty subgroups but greater improvements in HF-related symptoms. Moreover, semaglutide reduced frailty burden after 52 weeks of treatment. (Research Study to Investigate How Well S…
View article: Vascular Regenerative Cell Exhaustion in Adults With Peripheral Artery Disease
Vascular Regenerative Cell Exhaustion in Adults With Peripheral Artery Disease Open
View article: Elevated Lipoprotein(a) Levels and Massive Ruptured Root and Ascending Aortic Aneurysm
Elevated Lipoprotein(a) Levels and Massive Ruptured Root and Ascending Aortic Aneurysm Open
Elevated lipoprotein(a) may contribute to thoracic aortic aneurysm progression. Its role in risk stratification warrants further investigation.
View article: Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial
Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial Open
View article: Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure Open
BACKGROUND: SGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited. METHODS: We condu…
View article: Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial Open
Background and Aims Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major atherosclerotic cardiovascular events in individuals living with either diabetes or obesity. Since the turnover of vascular regenerative (VR) stem and pr…
View article: Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study
Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study Open
Aims Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD); however, the relationship between Lp(a) and the capacity for vascular repair remains unclear. Depletion of vascular regenerative (VR) p…
View article: The Emerging Role of Aldosterone Synthase Inhibitors in Overcoming Renin–Angiotensin–Aldosterone System Therapy Limitations: A Narrative Review
The Emerging Role of Aldosterone Synthase Inhibitors in Overcoming Renin–Angiotensin–Aldosterone System Therapy Limitations: A Narrative Review Open
The renin–angiotensin–aldosterone system is integral to cardiorenal health, with aldosterone controlling fluid balance, blood pressure and cardiac remodelling. Despite the widespread use of angiotensin-converting enzyme inhibitors, angiote…
View article: Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial Open
View article: Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The <scp>REALIZE</scp>‐K open‐label run‐in phase
Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The <span>REALIZE</span>‐K open‐label run‐in phase Open
No abstract available.
View article: Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial
Efficacy and safety of dapagliflozin in patients hospitalized with COVID-19 with and without type 2 diabetes: a prespecified analysis of the DARE-19 randomized trial Open
The trial was registered on ClinicalTrials.gov (NCT04350593).
View article: Impact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income Countries
Impact of Sex and Age on Trends of Mortality From Infective Endocarditis in High-Income Countries Open
Mortality rate from infective endocarditis is increasing in most countries, with varying patterns and degrees of changes observed in relation to sex and age. This underscores the crucial need to identify the root causes at the individual c…
View article: Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial Open
OBJECTIVE The Semaglutide and Walking Capacity in People with Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE) trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional …
View article: Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics; Insights from STRIDE, a Randomized, Placebo-controlled, Double-blind Trial
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics; Insights from STRIDE, a Randomized, Placebo-controlled, Double-blind Trial Open
Objective The STRIDE trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic peripheral artery disease (PAD) and …
View article: Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics; Insights from STRIDE, a Randomized, Placebo-controlled, Double-blind Trial
Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics; Insights from STRIDE, a Randomized, Placebo-controlled, Double-blind Trial Open
Objective The STRIDE trial (NCT04560998) showed that once-weekly subcutaneous semaglutide 1.0 mg significantly improved functional outcomes, symptoms, and quality of life in individuals with symptomatic peripheral artery disease (PAD) and …
View article: Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study Open
AIMS: Coronavirus disease 2019 (COVID-19) is caused by a novel severe acute respiratory syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and cardiovascular decompensation, and kidney injury, with significant…
View article: Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial Open
View article: Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement Open
Obesity rates have surged since 1990 worldwide. This rise is paralleled by increases in pathological processes affecting organs such as the heart, liver, and kidneys, here termed systemic metabolic disorders (SMDs). For clinical management…
View article: Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection
Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection Open
BACKGROUND AND OBJECTIVES: Patients who were hospitalized with coronavirus disease 2019 (COVID-19) infection are at high risk of AKI and KRT, especially in the presence of CKD. The Dapagliflozin in Respiratory Failure in Patients with COVI…
View article: The Global Implementation Guidelines Initiative: how to optimize cardio-renal-metabolic care worldwide
The Global Implementation Guidelines Initiative: how to optimize cardio-renal-metabolic care worldwide Open
View article: Safety and efficacy of empagliflozin in heart failure among patients with a history of valvular heart disease: Insights from EMPEROR-Pooled
Safety and efficacy of empagliflozin in heart failure among patients with a history of valvular heart disease: Insights from EMPEROR-Pooled Open
We present the first large analysis of SGLT2i (empagliflozin) use in HF patients by history of VHD. Although VHD history was associated with worse outcomes in HF patients, empagliflozin demonstrated consistent safety, efficacy, and patient…
View article: Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial Open
Background and Aims Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time…
View article: Generalizability of SELECT to Cardiac Surgical Patients
Generalizability of SELECT to Cardiac Surgical Patients Open
View article: Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery
Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery Open
Among individuals undergoing surgical revascularization for CAD, lipoprotein(a) levels may help define risk and inform best practices for perioperative management. We advocate for the routine measurement of lipoprotein(a) in all patients u…
View article: Association between white blood cell count and coronary artery bypass graft failure: an individual patient data analysis of clinical trials
Association between white blood cell count and coronary artery bypass graft failure: an individual patient data analysis of clinical trials Open
View article: Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial Open
View article: How I do it ─ superficial parasternal intercostal plane catheter insertion
How I do it ─ superficial parasternal intercostal plane catheter insertion Open
View article: Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide
Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide Open
View article: Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction Open
In patients with HF with mildly reduced/preserved ejection fraction, the beneficial effects of finerenone on clinical events and symptoms were consistent, irrespective of BMI at baseline, possibly with a greater effect on the primary outco…